

DOCKET NO.: ALZA-0023/ARC2865N1

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Lam, et al

Confirmation No.: 1161

Application No.: 09/802,709

Group Art Unit: 1614

Filing Date: March 8, 2001

Examiner: Z. Fay

For: Methods And Devices For Providing Drug Therapy

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56, information relating to the above-identified application is hereby disclosed. The documents identified in the accompanying Form PTO 1449 relate to parent patent application 09/253,317, and are identified on their face as having recently been transmitted to Applicants by third parties pursuant to the provisions of 21 U.S.C. §365(j)(2)(B)(i) and (ii). The documents are provided in the interest of full disclosure, and their inclusion in this statement is not to be construed as an admission that information contained therein is material as that term is defined in 37 CFR § 1.56(b), or that Applicants concur in the arguments expressed. As will be noted, for example, the patent that is identified in the paragraph spanning pages 3 and 4 of Document 71 (i.e. U.S. 4,915,953) is not believed to be material since it is a continuation of a patent (i.e. U.S. 4,814,181) that already is of record in the instant patent application. Moreover, the pending claims are believed to be definite within the meaning of 35 U.S.C. §112.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: August 8, 2005

Registration No. 33,396

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW





Form PTO-1449 Modified			Docket No ALZA-00	o. 23(ARC2865N1)	Application No. 09/802,709
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)			Applicant Lam, et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Dat March 8,		Group 1614
			Confirmat 1161	ion No.	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	70	Letter from Ted Whitlock, Intellectual Property Counsel, Andrx Pharmaceuticals, LLC. to McNeil Consumers & Specialty Pharmaceuticals, Re: ANDA for Concerta® Extended-release Tablets 54 mg; July 20, 2005, 39 pages			
	71	Letter from Ted Whitlock, Intellectual Property Counsel, Andrx Pharmaceuticals, LLC. to McNeil Consumers & Specialty Pharmaceuticals, Re: ANDA for Concerta® Extended-release Tablets 18, 27, and 36 mg; July 20, 2005, 11 pages			
	72	Letter from Mark C. Shaw, Vice-President, Regulatory Affairs and Compliance, IMPAX Laboratories, Inc., to McNeil Consumer and Specialty Pharmaceuticals & ALZA Corporation, Re: Notice Under 21 U.S.C. §355(j)(2)(B)(i) and (ii), With Reference to U.S. Patent No. 6,919,373, July 20, 2005, 13 pages			
EXAMINER				DATE CONSIDERED	